RANK-and c-Met-mediated signal network promotes prostate cancer metastatic colonization

Endocrine-Related Cancer

Volumn 21, Issue 2, 2014, Pages 311-326

  Chu, Gina Chia Yi ^a   Zhau, Haiyen E ^a   Wang, Ruoxiang ^a   Rogatko, Andre ^b   Feng, Xu ^c   Zayzafoon, Majd ^c   Liu, Youhua ^d   Farach Carson, Mary C ^e   You, Sungyong ^b   Kim, Jayoung ^b   Freeman, Michael R ^a,b   Chung, Leland W K ^a,b  

^a Samuel Oschin Comprehensive Cancer Institute   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e RICE UNIVERSITY   (United States)

Author keywords

C Met; Cancer dormancy; Metastasis; Prostate cancer; RANK; RANKL

Indexed keywords

ANDROGEN RECEPTOR; AP4 PROTEIN; HEPATOCYTE NUCLEAR FACTOR 3BETA; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; ORGANIC CATION TRANSPORTER 3; OSTEOCLAST DIFFERENTIATION FACTOR; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTION FACTOR TWIST1; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTION FACTOR ZEB2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER LOCALIZATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE REPRESSION; GENETIC ANALYSIS; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LNCAP CELL LINE; MALE; MOUSE; NEUROENDOCRINE SYSTEM; NONHUMAN; NUCLEAR REPROGRAMMING; NUCLEOTIDE SEQUENCE; POSITIVE FEEDBACK; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; STEM CELL; TRANSCRIPTION FACTOR DELETION INTERFERENCE ASSAY; TUMOR GROWTH; WESTERN BLOTTING;

C-MET; CANCER DORMANCY; METASTASIS; PROSTATE CANCER; RANK; RANKL;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS;

EID: 84899864278     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0548     Document Type: Article

References (54)

1. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC et al. 2010 Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29 811-821. (doi:10.1038/onc. 2009.389)
2. Ando K, Mori K, Redini F & Heymann D 2008 RANKL/RANK/OPG: key therapeutic target in bone oncology. Current Drug Discovery Technologies 5 263-268. (doi:10.2174/157016308785739857)
3. Birchmeier C, Birchmeier W, Gherardi E & Vande Woude GF 2003 Met, metastasis, motility and more. Nature Reviews. Molecular Cell Biology 4 915-925. (doi:10.1038/nrm1261)
4. Cai J, Guan H, Fang L, Yang Y, Zhu X, Yuan J, Wu J & Li M 2013 MicroRNA-374a activates Wnt/b-catenin signaling to promote breast cancer metastasis. Journal of Clinical Investigation 123 566-579. (doi:10.1172/ JCI65871)
5. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H et al. 2010 The transcriptional network for mesenchymal transformation of brain tumours. Nature 463 318-325. (doi:10.1038/nature08712)
6. Cole MD & McMahon SB 1999 The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 18 2916-2924. (doi:10.1038/sj.onc.1202748)
7. Coleman RE 2001 Metastatic bone disease: clinical features, pathophy-siology and treatment strategies. Cancer Treatment Reviews 27 165-176. (doi:10.1053/ctrv.2000.0210)
8. De Marzo AM, Knudsen B, Chan-Tack K & Epstein JI 1999 E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 53 707-713. (doi:10.1016/S0090-4295(98)00577-9)
9. Dougall WC 2011 Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis. Clinical Cancer Research 18 326-335. (doi:10.1158/1078-0432.CCR-10- 2507)
10. Gherardi E, Birchmeier W, Birchmeier C & Vande Woude G 2012 Targeting MET in cancer: rationale and progress. Nature Reviews. Cancer 12 89-103. (doi:10.1038/nrc3205)
11. Griffith OL, Montgomery SB, Bernier B, Chu B, Kasaian K, Aerts S, Mahony S, Sleumer MC, Bilenky M, Haeussler M et al. 2008 ORegAnno: an open-access community-driven resource for regulatory annotation. Nucleic Acids Research 36 D107-D113. (doi:10.1093/nar/gkm967)
12. Hanada R, Leibbrandt A, Hanada T, Kitaoka S, Furuyashiki T, Fujihara H, Trichereau J, Paolino M, Qadri F, Plehm R et al. 2009 Central control of fever and female body temperature by RANKL/RANK. Nature 462 505-509. (doi:10.1038/nature08596)
13. Hiraga T, Myoui A, Hashimoto N, Sasaki A, Hata K, Morita Y, Yoshikawa H, Rosen CJ, Mundy GR & Yoneda T 2012 Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Research 72 4238-4249. (doi:10.1158/0008-5472.CAN-11-3061)
14. Hu P, Chung LW, Berel D, Frierson HF, Yang H, Liu C, Wang R, Li Q, Rogatko A & Zhau HE 2013 Convergent RANK-and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study. PLoS ONE 8 e73081. (doi:10.1371/journal.pone.0073081)
15. Huang WC, Wu D, Xie Z, Zhau HE, Nomura T, Zayzafoon M, Pohl J, Hsieh CL, Weitzmann MN, Farach-Carson MC et al. 2006 b2-Microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis. Cancer Research 66 9108-9116. (doi:10.1158/0008-5472.CAN-06-1996)
16. Huang WC, Zhau HE & Chung LW 2010 Androgen receptor survival signaling is blocked by anti-b2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells. Journal of Biological Chemistry 285 7947-7956. (doi:10.1074/jbc.M109.092759)
17. Huang da W, Sherman BT & Lempicki RA 2009 Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 4 44-57. (doi:10.1038/nprot.2008.211)
18. Hwang D, Rust AG, Ramsey S, Smith JJ, Leslie DM, Weston AD, de Atauri P, Aitchison JD, Hood L, Siegel AF et al. 2005 A data integration methodology for systems biology. PNAS 102 17296-17301. (doi:10.1073/pnas.0508647102)
19. Josson S, Nomura T, Lin JT, Huang WC, Wu D, Zhau HE, Zayzafoon M, Weizmann MN, Gururajan M & Chung LW 2011 b2-Microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Research 71 2600-2610. (doi:10.1158/0008-5472.CAN-10- 3382)
20. Jung P, Menssen A, Mayr D & Hermeking H 2008 AP4 encodes a c-MYC-inducible repressor of p21. PNAS 105 15046-15051. (doi:10.1073/pnas. 0801773105)
21. Knudsen BS & Edlund M 2004 Prostate cancer and the met hepatocyte growth factor receptor. Advances in Cancer Research 91 31-67. (doi:10.1016/S0065-230X(04)91002-0)
22. Kong D, Li Y, Wang Z & Sarkar FH 2011 Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancer 3 716-729. (doi:10.3390/cancers30100716)
23. Lachmann A, Xu H, Krishnan J, Berger SI, Mazloom AR & Ma'ayan A 2010 ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics 26 2438-2444. (doi:10.1093/bioinformatics/ btq466)
24. van Leenders GJ, Sookhlall R, Teubel WJ, de Ridder CM, Reneman S, Sacchetti A, Vissers KJ, van Weerden W & Jenster G 2011 Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS ONE 6 e26753. (doi:10.1371/journal.pone.0026753)
25. Li X, Ominsky MS, Stolina M, Warmington KS, Geng Z, Niu QT, Asuncion FJ, Tan HL, Grisanti M, Dwyer D et al. 2009 Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin. Bone 45 669-676. (doi:10.1016/j.bone.2009.06.011)
26. Linhart C, Halperin Y & Shamir R 2008 Transcription factor and microRNA motif discovery: the Amadeus platform and a compendium of metazoan target sets. Genome Research 18 1180-1189. (doi:10.1101/gr.076117.108)
27. Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Lu X et al. 2011 VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging a4b1-positive osteoclast progenitors. Cancer Cell 20 701-714. (doi:10.1016/j.ccr.2011.11.002)
28. McHugh NA, Vercesi HM, Egan RW & Hey JA 2003 Receptor activator of NF-kB ligand arrests bone growth and promotes cortical bone resorption in growing rats. Journal of Applied Physiology 95 672-676. (doi:10.1152/ japplphysiol.00056.2003)
29. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M & Wu H 2012 Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Research 72 1878-1889. (doi:10.1158/0008-5472.CAN-11-3132)
30. Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, eVere White RW, Kung HJ, Evans CP & Gao AC 2012 MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. Journal of Biological Chemistry 287 1527-1537. (doi:10.1074/jbc.M111. 278705)
31. Nuche-Berenguer B, Lozano D, Gutierrez-Rojas I, Moreno P, Marinoso ML, Esbrit P & Villanueva-Penacarrillo ML 2011 GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia. Journal of Endocrinology 209 203-210. (doi:10.1530/JOE-11-0015)
32. Odero-Marah VA, Wang R, Chu G, Zayzafoon M, Xu J, Shi C, Marshall FF, Zhau HE & Chung LW 2008 Receptor activator of NF-kB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Research 18 858-870. (doi:10.1038/cr.2008.84)
33. Organ SL & Tsao MS 2011 An overview of the c-MET signaling pathway. Therapeutic Advances in Medical Oncology 3 S7-S19. (doi:10.1177/ 1758834011422556)
34. Paland N, Kamer I, Kogan-Sakin I, Madar S, Goldfinger N & Rotter V 2009 Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer. Molecular Cancer Research 7 1212-1223. (doi:10.1158/1541-7786.MCR-09- 0073)
35. Park SI, Soki FN & McCauley LK 2011 Roles of bone marrow cells in skeletal metastases: no longer bystanders. Cancer Microenvironment 4 237-246. (doi:10.1007/s12307-011-0081-8)
36. Pathak S, Nemeth MA, Multani AS, Thalmann GN, von Eschenbach AC & Chung LW 1997 Can cancer cells transform normal host cells into malignant cells? British Journal of Cancer 76 1134-1138. (doi:10.1038/bjc.1997.524)
37. Portales-Casamar E, Kirov S, Lim J, Lithwick S, Swanson MI, Ticoll A, Snoddy J & Wasserman WW 2007 PAZAR: a framework for collection and dissemination of cis-regulatory sequence annotation. Genome Biology 8 R207. (doi:10.1186/gb-2007-8-10-r207)
38. Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, Krajewski S, Mercola D, Carpenter PM, Bowtell D et al. 2010 Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendo-crine phenotype and neuroendocrine prostate tumors. Cancer Cell 18 23-38. (doi:10.1016/j.ccr.2010. 05.024)
39. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA & Pollard JW 2011 CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475 222-225. (doi:10.1038/ nature10138)
40. Reimand J, Arak T & Vilo J 2011 g:Profiler-A web server for functional interpretation of gene lists (2011 update). Nucleic Acids Research 39 W307-W315. (doi:10.1093/nar/gkr378)
41. Sanbe T, Tomofuji T, Ekuni D, Azuma T, Irie K, Tamaki N, Yamamoto T & Morita M 2009 Vitamin C intake inhibits serum lipid peroxidation and osteoclast differentiation on alveolar bone in rats fed on a high-cholesterol diet. Archives of Oral Biology 54 235-240. (doi:10.1016/j.archoralbio.2008.11.001)
42. Severin J, Waterhouse AM, Kawaji H, Lassmann T, van Nimwegen E, Balwierz PJ, de Hoon MJ, Hume DA, Carninci P, Hayashizaki Y et al. 2009 FANTOM4 EdgeExpressDB: an integrated database of promoters, genes, microRNAs, expression dynamics and regulatory interactions. Genome Biology 10 R39. (doi:10.1186/gb-2009-10-4-r39)
43. K breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Research 8 R59. (doi:10.1186/bcr1610)
44. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS et al. 2013 Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. Journal of Clinical Oncology 31 412-419. (doi:10.1200/JCO.2012.45.0494)
45. Storey J & Tibshirani R 2003 Statistical methods for detecting differential gene expression. In Functional Genomics: Methods and Protocols, pp 111-136. Eds MJ Brownstein & AB Khodursky. Totowa, NJ: Methods in Molecular Biology series, 224 Humana Press.
46. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al. 2005 Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. PNAS 102 15545-15550. (doi:10.1073/pnas.0506580102)
47. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM & Karin M 2011 Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470 548-553. (doi:10.1038/nature09707)
48. Thomas GP, Baker SU, Eisman JA & Gardiner EM 2001 Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. Journal of Endocrinology 170 451-460. (doi:10.1677/joe.0.1700451)
49. Verras M, Lee J, Xue H, Li TH, Wang Y & Sun Z 2007 The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Research 67 967-975. (doi:10.1158/0008-5472.CAN-06-3552)
50. Wu Z, Irizarry R, Gentleman R, Murillo F & Spencer F 2004 A model based background adjustment for oligonucleotide expression arrays. Journal of the American Statistical Association 99 909-917. (doi:10.1198/ 016214504000000683)
51. Xu J, Wang R, Xie ZH, Odero-Marah V, Pathak S, Multani A, Chung LW & Zhau HE 2006 Prostate cancer metastasis: role of the host micro-environment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate 66 1664-1673. (doi:10.1002/pros.20488)
52. Yang X, Shi C, Tong R, Qian W, Zhau HE, Wang R, Zhu G, Cheng J, Yang VW, Cheng T et al. 2010 Near IR heptamethine cyanine dye-mediated cancer imaging. Clinical Cancer Research 16 2833-2844. (doi:10.1158/1078-0432.CCR-10-0059)
53. Zhao F, Xuan Z, Liu L & Zhang MQ 2005 TRED: a Transcriptional Regulatory Element Database and a platform for in silico gene regulation studies. Nucleic Acids Research 33 D103-D107. (doi:10.1093/nar/gki004)
54. Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, Chu G, Liu ZR, Zhou BP, Huang WC & Chung LW 2008 Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clinical & Experimental Metastasis 25 601-610. (doi:10.1007/s10585-008-9183-1)